Recursion Pharmaceuticals, Inc. (RXRX) is a Biotechnology company in the Healthcare sector, currently trading at $3.54. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is RXRX = $11 (+210.7% upside).
Valuation: RXRX trades at a trailing Price-to-Earnings (P/E) of -2.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.23.
Financials: revenue is $75M, +23.8%/yr average growth. Net income is $645M (loss), growing at -39.1%/yr. Net profit margin is -863.4% (negative). Gross margin is -62% (-40.3 pp trend).
Balance sheet: total debt is $78M against $1.1B equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 5.5 (strong liquidity). Debt-to-assets is 5.3%. Total assets: $1.5B.
Analyst outlook: 4 / 10 analysts rate RXRX as buy (40%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 12/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).
